AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25926600 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive PF4/H-PaGIA result.
Number of subjects: 526
Study 25926790 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-action video game training (20 sessions, 1 hour each)
Number of subjects: 2
Study 25926790 — intervention group
Group type: COMPARATOR
Intervention: Control group (attended meetings with research team, no training)
Number of subjects: 2
Study 25926790 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-action video game training
Number of subjects: 2
Study 25926790 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 25926858 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/cobicistat 800/150 mg once daily
Number of subjects: 313
Study 25927357 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) using the iPro(®)2 system
Number of subjects: 84
Study 25927357 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 84
Study 25927357 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of glycemic control using CGM
Number of subjects: 84
Study 25927460 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Blood Management (PBM) program
Number of subjects: 0
Study 25927460 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation cohort
Number of subjects: 0
Study 25927526 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR testing in HIV-positive cases
Number of subjects: 525
Study 25927526 — intervention group
Group type: COMPARATOR
Intervention: PCR testing in HIV-negative well-controls
Number of subjects: 525
Study 25927526 — intervention group
Group type: COMPARATOR
Intervention: PCR testing in HIV-positive well-controls
Number of subjects: 525
Study 25927526 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopy testing in HIV-positive cases
Number of subjects: 525
Study 25927526 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture testing in HIV-positive cases
Number of subjects: 525
Study 25927526 — intervention group
Group type: EXPERIMENTAL
Intervention: Culture testing in HIV-negative cases
Number of subjects: 525
Study 25927526 — intervention group
Group type: COMPARATOR
Intervention: Culture testing in HIV-negative specimens
Number of subjects: 525
Study 25927526 — intervention group
Group type: COMPARATOR
Intervention: Culture testing in HIV-positive specimens
Number of subjects: 525
Study 25927528 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response Mind-Body Intervention (RR-MBI)
Number of subjects: 48
Study 25927615 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer monitoring using ActiGraph GT3X+ for 7 days with a 24-hr waist worn protocol.
Number of subjects: 7806
Study 25927915 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspergillus lateral-flow device (LFD) test for BAL IPA detection
Number of subjects: 133
Study 25927915 — intervention group
Group type: COMPARATOR
Intervention: Fungal BAL culture
Number of subjects: 133
Study 25927980 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Medical Services (EMS) treatment for OHCA
Number of subjects: 0
Study 25928189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Bispectral Index (BIS)-monitoring during pre-, intra- and postoperative period
Number of subjects: 81
Study 25928189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral BIS monitoring
Number of subjects: 81
Study 25928189 — intervention group
Group type: EXPERIMENTAL
Intervention: Burst Suppression Ratio (BSR)
Number of subjects: 81
Study 25928811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (1,000 mg iron)
Number of subjects: 30
Study 25928811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 30
Study 25929250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicoboxil/nonivamide ointment
Number of subjects: 805
Study 25929250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicoboxil ointment
Number of subjects: 805
Study 25929250 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonivamide ointment
Number of subjects: 805
Study 25929250 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 805
Study 25929276 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripapillary retinal nerve fiber layer (RNFL) measurement
Number of subjects: 43
Study 25929276 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized normal appearing white matter volume
Number of subjects: 43
Study 25929582 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib combined with cisplatin/gemcitabine (starting dose 5 mg bid, titrated to 2-10 mg bid; cisplatin 80 mg/m2 i.v. every 3 weeks; gemcitabine 1,250 mg/m2 i.v. on days 1 and 8 of each 3-week cycle)
Number of subjects: 38
Study 25929664 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 531
Study 25929739 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg b.i.d.
Number of subjects: 293
Study 25929739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 25929922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir monotherapy (mtDRV/rtv)
Number of subjects: 71
Study 25930082 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MENG recordings
Number of subjects: 0
Study 25930082 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative MENG recordings
Number of subjects: 0
Study 25930082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative recordings
Number of subjects: 0
Study 25930082 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MENG data
Number of subjects: 0
Study 25931518 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib (20 mg/kg, i.p., three times a week) and MK-2206 (60 mg/kg, orally, three times a week)
Number of subjects: 8
Study 25932660 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels in plasma and bronchoalveolar fluid of acid-injured mice
Number of subjects: 30
Study 25932660 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels in plasma of patients with ARDS
Number of subjects: 30
Study 25932660 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels over time in mice
Number of subjects: 30
Study 25932660 — intervention group
Group type: EXPERIMENTAL
Intervention: sRAGE levels and lung injury severity
Number of subjects: 30
Study 25932696 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 94
Study 25932696 — intervention group
Group type: COMPARATOR
Intervention: Formula milk
Number of subjects: 94
Study 25932696 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger gestational age at birth
Number of subjects: 94
Study 25932696 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of medical complications (neurological risk, bronchopulmonary dysplasia, necrotizing enterocolitis, patent ductus arteriosus)
Number of subjects: 94
Study 25932696 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroesophageal reflux disease
Number of subjects: 94
Study 25932797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction (4 hours of sleep)
Number of subjects: 12
Study 25932797 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery (8 hours of sleep)
Number of subjects: 12
Study 25933168 — intervention group
Group type: EXPERIMENTAL
Intervention: CPS-immunization
Number of subjects: 16
Study 25933809 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of imaging and CEA follow-up
Number of subjects: 0
Study 25933833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilorasertib (540 mg once weekly and 480 mg twice weekly)
Number of subjects: 52
Study 25933833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilorasertib (oral)
Number of subjects: 52
Study 25934187 — intervention group
Group type: COMPARATOR
Intervention: Presence of mtDNA polymorphisms at positions 16519 and 3010 in individuals with functional syndromes.
Number of subjects: 0
Study 25934475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination DFX-deferoxamine (DFO)
Number of subjects: 60
Study 25934759 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 80
Study 25935493 — intervention group
Group type: EXPERIMENTAL
Intervention: Spent culture media (SCM) from embryos of obese women (n = 16)
Number of subjects: 28
Study 25935493 — intervention group
Group type: COMPARATOR
Intervention: Spent culture media (SCM) from embryos of normoweight women (n = 12)
Number of subjects: 28
Study 25935574 — intervention group
Group type: EXPERIMENTAL
Intervention: CDEIS
Number of subjects: 50
Study 25935574 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-CD
Number of subjects: 50
Study 25935574 — intervention group
Group type: EXPERIMENTAL
Intervention: GELS
Number of subjects: 50
Study 25935574 — intervention group
Group type: EXPERIMENTAL
Intervention: CDEIS and GELS
Number of subjects: 50
Study 25935574 — intervention group
Group type: EXPERIMENTAL
Intervention: SES-CD and GELS
Number of subjects: 50
Study 25935574 — intervention group
Group type: EXPERIMENTAL
Intervention: CDEIS and SES-CD
Number of subjects: 50
Study 25935582 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (5 years)
Number of subjects: 4861
Study 25935582 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (5 years)
Number of subjects: 4861
Study 25935794 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clarithromycin (2 g/day, oral, days 1-14, every 21 days)
Number of subjects: 23
Study 25936321 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis treatment with atorvastatin
Number of subjects: 30
Study 25936321 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 30
Study 25936396 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in hippocampal volume (measured by fit slope)
Number of subjects: 27
Study 25936396 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in hippocampal volume (measured by percentage change)
Number of subjects: 27
Study 25936597 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression for 12 months and radiation therapy (25 Gy to pelvic nodes and 40 Gy to prostate, 1 fraction per week over 5 weeks)
Number of subjects: 16
Study 25936597 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen suppression for 12 months and radiation therapy
Number of subjects: 16
Study 25936984 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal gene therapy
Number of subjects: 3
Study 25937263 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose alkylating chemotherapy (HDAC) based on BRCA1-like testing
Number of subjects: 0
Study 25937263 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study 25937263 — intervention group
Group type: EXPERIMENTAL
Intervention: BRCA1-like testing
Number of subjects: 0
Study 25937426 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide 160mg/day
Number of subjects: 67
Study 25937431 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg) administered via gastrostomy feeding tube (GT) in fasting state and supine position.
Number of subjects: 6
Study 25937431 — intervention group
Group type: COMPARATOR
Intervention: Dacomitinib via GT
Number of subjects: 6
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic trial enrollment
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial availability
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with trial ineligibility
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment odds for non-White patients
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrollment odds for patients of Black physicians
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that trial may help
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about care if not on trial
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure to enroll
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving without pay
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician belief about standard therapy
Number of subjects: 781
Study 25937529 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician belief about trial time consumption
Number of subjects: 781
Study 25937606 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurant stent graft in REG anatomy
Number of subjects: 1218
Study 25937606 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurant stent graft in INT anatomy
Number of subjects: 1218
Study 25937606 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurant stent graft in CHA anatomy
Number of subjects: 1218
Study 25937868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/d in 6-wk cycles (4 wk on treatment followed by 2 wk off treatment)
Number of subjects: 3
Study 25937868 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg/d
Number of subjects: 3
Study 25938001 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus 175/75 mg
Number of subjects: 162
Study 25938001 — intervention group
Group type: COMPARATOR
Intervention: INV (investigator's choice of therapy)
Number of subjects: 162
Study 25938124 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session HIV education
Number of subjects: 148
Study 25938124 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-session HIV education
Number of subjects: 148
Study 25938124 — intervention group
Group type: COMPARATOR
Intervention: No HIV education (control group)
Number of subjects: 148
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life measured by SGRQ score
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic bronchitis
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheezing
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of exacerbations in the year before inclusion
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-min walking distance
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 (% predicted)
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: DLCO (% predicted)
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 2006 classification
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 2011 classification
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: BODE index
Number of subjects: 273
Study 25938292 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis model including age, chronic bronchitis, dyspnea (MRC scale), diffusing lung capacity and 6-min walking distance
Number of subjects: 273
Study 25938519 — intervention group
Group type: EXPERIMENTAL
Intervention: hNSCs differentiated on 3D scaffolds
Number of subjects: 0
Study 25938638 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy with rAAV2/2 RPE65 vector
Number of subjects: 12
Study 25939066 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (specific dosage and duration not mentioned)
Number of subjects: 428
Study 25939066 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed pregnant women (control group)
Number of subjects: 428
Study 25939067 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole
Number of subjects: 0
Study 25939067 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25939704 — intervention group
Group type: COMPARATOR
Intervention: Bone geometry, volumetric BMD, and micro-architecture measurements using HR-pQCT
Number of subjects: 18
Study 25939704 — intervention group
Group type: COMPARATOR
Intervention: Bone stiffness and strength measurements
Number of subjects: 18
Study 25939704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-collagen type 1 N-terminal pro-peptide (P1NP) levels
Number of subjects: 18
Study 25939720 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 rs738409 G allele (148Met) presence in overweight/obese with MetS
Number of subjects: 288
Study 25939720 — intervention group
Group type: EXPERIMENTAL
Intervention: CG and GG genotypes
Number of subjects: 288
Study 25939720 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygote G allele in individuals aged below 20 years
Number of subjects: 288
Study 25940115 — intervention group
Group type: EXPERIMENTAL
Intervention: Older women (>35 years)
Number of subjects: 3472
Study 25940115 — intervention group
Group type: EXPERIMENTAL
Intervention: Women aged 25-34 years
Number of subjects: 3472
Study 25940115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of education
Number of subjects: 3472
Study 25940115 — intervention group
Group type: EXPERIMENTAL
Intervention: Having >1 life-time sexual partners
Number of subjects: 3472
Study 25940115 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity >1
Number of subjects: 3472
Study 25940115 — intervention group
Group type: EXPERIMENTAL
Intervention: Being HIV positive
Number of subjects: 3472
Study 25940342 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 160
Study 25940342 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 25941185 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial biomarker algorithm using a simple blood-based marker (aspartate aminotransferase:ALT ratio for hazardous alcohol users, BARD score for other risk groups) and liver stiffness measurement using transient elastography (TE)
Number of subjects: 504
Study 25941185 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive liver investigation algorithm targeting risk factors
Number of subjects: 504
Study 25941189 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied three times per week for 6 months at 30 minutes per treatment.
Number of subjects: 112
Study 25941220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1 g
Number of subjects: 12
Study 25941220 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 g
Number of subjects: 12
Study 25942403 — intervention group
Group type: EXPERIMENTAL
Intervention: HTG subjects (with or without statin)
Number of subjects: 15773
Study 25942403 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects on statin
Number of subjects: 15773
Study 25942403 — intervention group
Group type: EXPERIMENTAL
Intervention: HTG (with or without statin)
Number of subjects: 15773
Study 25942403 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 15773
Study 25942403 — intervention group
Group type: COMPARATOR
Intervention: Statin treatment
Number of subjects: 15773
Study 25942403 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride reduction
Number of subjects: 15773
Study 25942723 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) fixed-dose combination, administered twice daily for 12 weeks.
Number of subjects: 415
Study 25942724 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) with ribavirin (1000-1200 mg/d)
Number of subjects: 202
Study 25942724 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir (30 mg), asunaprevir (200 mg), and beclabuvir (75 mg) without ribavirin
Number of subjects: 202
Study 25943162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular rate (VR) ≤ 60 bpm (low VR)
Number of subjects: 2821
Study 25943162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular rate (VR) ≥ 160 bpm (high VR)
Number of subjects: 2821
Study 25943162 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (ECV)
Number of subjects: 2821
Study 25943162 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradycardia
Number of subjects: 2821
Study 25943162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboembolic complications
Number of subjects: 2821
Study 25943162 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of AF
Number of subjects: 2821
Study 25944344 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily
Number of subjects: 22
Study 25944628 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting serum insulin
Number of subjects: 15288
Study 25944628 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR (homeostasis model assessment-insulin resistance)
Number of subjects: 15288
Study 25944628 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum-triglyceride-to-serum-high-density lipoprotein-cholesterol ratio (TG/HDL-C)
Number of subjects: 15288
Study 25944628 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (serum glucose ≥110 mg/dL)
Number of subjects: 15288
Study 25944628 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 15288
Study 25944628 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 15288
Study 25944628 — intervention group
Group type: EXPERIMENTAL
Intervention: TG/HDL-C
Number of subjects: 15288
Study 25944628 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 15288
Study 25944633 — intervention group
Group type: EXPERIMENTAL
Intervention: Full coverage for β-blockers, renin-angiotensin system antagonists, and statins without cost sharing
Number of subjects: 0
Study 25944633 — intervention group
Group type: COMPARATOR
Intervention: Usual coverage for β-blockers, renin-angiotensin system antagonists, and statins at the current level of insurance coverage
Number of subjects: 0
Study 25944633 — intervention group
Group type: COMPARATOR
Intervention: Comparison of full coverage to usual coverage
Number of subjects: 0
Study 25944758 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve replacement with the Melody valve
Number of subjects: 171
Study 25944802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan at 12 mg/kg (maximum tolerated dose for cycle 1)
Number of subjects: 25